Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group
作者: Ignace VergotePhilip DebruyneFrédéric KridelkaPatrick BertelootFrédéric AmantBrigitte HonhonWillem LybaertKarin LeunenKurt GeldhofDidier VerhoevenFrédéric ForgetPeter VuylstekeLionel D'HondtManon HuizingHeidi Van den BulckAnnouschka Laenen
作者单位: 1Gynecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium
2AZ Groeninge, Kortrijk, Belgium
3CHU de Liège, Liège, Belgium
4Grand Hôpital de Charleroi, Charleroi, Belgium
5AZ Nikolaas, St. Niklaas, Belgium
6Jan Yperman ziekenhuis, Ieper, Belgium
7AZ Klina, Brasschaat, Belgium
8CHA — Centre Hospitalier de l'Ardenne, Libramont, Belgium
9Clinique et Maternité Sainte Elisabeth, Namur, Belgium
10Cliniques universitaires UCL de Mont-Godinne, Yvoir, Belgium
11UZ Antwerpen, Edegem, Belgium
12Imeldaziekenhuis, Bonheiden, Belgium
13Leuvens Biostatistiek en Statistische Bioinformatica Centrum, Leuven, Belgium
刊名: Gynecologic Oncology, 2015, Vol.138 (2), pp.278-284
来源数据库: Elsevier Journal
DOI: 10.1016/j.ygyno.2015.05.042
关键词: Ovarian cancerEndometrial cancerCervical cancerPaclitaxelCarboplatinG-CSF
原始语种摘要: Abstract(#br)Objective(#br)To investigate the addition of prophylactic G-CSF to each weekly paclitaxel/carboplatin course in patients with recurrent platinum-resistant ovarian (OC), or recurrent or advanced endometrial (EC) or cervical carcinoma (CC).(#br)Methods(#br)108 patients were enrolled i.e. 36 in each cohort. Eighteen courses of paclitaxel (60mg/m 2 ) and carboplatin (AUC 2.7) were administered weekly. G-CSF (filgrastim) was given to all patients on day 5 (and if needed on day 6).(#br)Results(#br)For patients with OC, 91% had platinum-resistant and 9% platinum-refractory disease. Median number of prior chemotherapy lines was 3 for OC, 1 for EC, and 1 for CC. Grade 3–4 neutropenia was observed in 34% of patients (95% CI: 26%–44%, P <...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:3.929 (2012)

×